RNAZ

Transcode Therapeutics, Inc. (RNAZ) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Transcode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapeutics for cancer. The company's lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b. The company has no approved products and has not generated revenue from product sales.

Subsequent to the reporting period, on October 8, 2025, the company acquired Polynoma, LLC (developer of seviprotimut-L) and secured a $25 million investment from DEFJ, LLC.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the nine months ended September 30, 2025, increased to $21.22 million from $10.84 million in the same period in 2024. This increase was primarily driven by a $9.68 million non-cash expense related to the change in fair value of warrant liabilities.
• Operating Expenses: Total operating expenses increased by $1.39 million year-over-year for the nine-month period. Research and Development (R&D) expenses rose by $1.88 million due to increased clinical trial spending and drug production costs. General and Administrative (G&A) expenses decreased by $0.49 million due to cost reduction measures and reduced stock compensation.
• Warrant Liability: The company recorded a significant non-cash loss of $9.68 million for the nine months ended September 30, 2025, due to the change in fair value of Series C and Series D warrant liabilities. All Series D warrants were exercised in the first quarter of 2025.
• Grant Income: Grant income increased to $0.52 million for the nine months ended September 30, 2025, compared to $0.04 million in the prior year, reflecting the recognition of income from a new NIH SBIR Award received in September 2024.

Guidance, Outlook, and Risks

• Liquidity and Going Concern: As of September 30, 2025, the company had $2.84 million in cash. Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year without additional capital. However, management believes that the September 30 cash balance combined with the $20 million cash received from the October 2025 investment will fund operations into the fourth quarter of 2026.
• Clinical Progress: The Phase 1a clinical trial for TTX-MC138 is ongoing with enrollment complete; analysis of results is underway. A Phase 2a trial is expected to commence in the first half of 2026.
• Subsequent Financing: On October 8, 2025, the company closed a $25 million investment (comprising $20 million cash and a $5 million promissory note) and acquired Polynoma, LLC. This transaction significantly alters the company's capital structure and asset base.
• Risks: Key risks include the need for additional financing, potential delisting from Nasdaq, reliance on third-party vendors for clinical trials, and the uncertainty of regulatory approval for therapeutic candidates.

Investor Verification Checklist

• Capital Runway: Verify the sufficiency of the $20 million October 2025 cash infusion to cover the projected burn rate through Q4 2026, given the historical cash burn of ~$11.4 million over nine months.
• Warrant Liability Volatility: Assess the impact of the remaining Series C warrant liability ($0.83 million) on future earnings, as fair value changes can cause significant non-cash volatility in net loss.
• Acquisition Integration: Review the terms of the Polynoma acquisition and the associated contingent milestone payments (up to $95 million) to understand future cash obligations.
• Clinical Trial Data: Monitor the release of Phase 1a trial results for TTX-MC138 to validate safety and dosing for the planned Phase 2a trial.
• Nasdaq Compliance: Confirm continued compliance with Nasdaq listing requirements, particularly regarding minimum bid price and equity market value, following the recent reverse stock splits and financing activities.